The Novartis decision of the Indian Supreme Court rejecting patentability of the cancer drug, Imatinib Mesylate in its beta crystalline form (commonly called 'Glivac'),...
Read more about The 3D Effect of Novartis Case on Genetic InventionsIP News Center
The Novartis decision of the Indian Supreme Court rejecting patentability of the cancer drug, Imatinib Mesylate in its beta crystalline form (commonly called 'Glivac'),...
Read more about The 3D Effect of Novartis Case on Genetic Inventions